Advances in Nanomaterial-Based Drug Delivery Systems
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Nanomedicine and Nanobiology".
Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 3128
Special Issue Editor
Special Issue Information
Dear Colleagues,
I would like to invite you to contribute new discoveries that may help advance the applications of nanotechnology in drug delivery.
Nanotechnology has been utilized in clinics. For example, two nanomedicines, liposome-based doxorubicin (Doxil) and albumin-conjugated paclitaxel (Abraxane), have been approved by the FDA for cancer chemotherapy. The recent success of mRNA COVID-19 vaccines has meant the development of nanotechnology-driven drug delivery systems has thrived.
Despite remarkable progress in the past few decades, challenges are still associated with nanomedicine. Biological barriers limit nanoparticles’ delivery of therapeutic drugs to the desired tissues or cells. The low efficiency of clinical translation indicates that there are safety and regulation issues. This Special Issue aims to publish up-to-date progress in engineering novel nanomaterials and formulations for delivering small-molecule and biologic drugs, strategies of enhancing the therapeutic outcome in treating diseases, such as cancer and autoimmune and infectious diseases, and mechanisms of improving the delivery efficiency of nanoparticles. I hope the contributions to this Special Issue will cast some light on improving the therapeutic effect and reducing the side effects of nanoparticle-based drug delivery systems in cancer therapy, gene therapy, and immunotherapy.
Dr. Donghui Song
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology
- drug delivery
- nanomedicine
- delivery efficiency
- cancer therapy
- gene therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
